Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertensions

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 3, 2015, Pages 480-489

  Liles, John T ^a   Hoyer, Kirsten ^a   Oliver, Jason ^a   Chi, Liguo ^a   Dhalla, Arvinder K ^a   Belardinelli, Luiz ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; RANOLAZINE; ACETANILIDE DERIVATIVE; COLLAGEN; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; HEART ARRHYTHMIA; HEART DEATH; HEART PROTECTION; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QT INTERVAL; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FIBROSIS; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACETANILIDES; ANIMALS; ARRHYTHMIAS, CARDIAC; COLLAGEN; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FIBROSIS; HYPERTENSION, PULMONARY; IN VITRO TECHNIQUES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 84936806481     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221861     Document Type: Article

References (40)

1. Abraham T, Wu G, Vastey F, Rapp J, Saad N, and Balmir E (2010) Role of combination therapy in the treatment of pulmonary arterial hypertension. Pharmacotherapy 30:390-404.
2. Aistrup GL, Gupta DK, Kelly JE, O'Toole MJ, Nahhas A, Chirayil N, Misener S, Beussink L, Singh N, Ng J, et al. (2013) Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol 305:H1068-H1079.
3. Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, and Belardinelli L (2014) The role of late I Na in development of cardiac arrhythmias. Handbook Exp Pharmacol 221:137-168.
4. Archer SL, Fang YH, Ryan JJ, and Piao L (2013) Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 3:144-152.
5. Benoist D, Stones R, Drinkhill M, Bernus O, and White E (2011) Arrhythmogenic substrate in hearts of rats with monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 300: H2230-H2237.
6. Benoist D, Stones R, Drinkhill MJ, Benson AP, Yang Z, Cassan C, Gilbert SH, Saint DA, Cazorla O, Steele DS, et al. (2012) Cardiac arrhythmia mechanisms in rats with heart failure induced by pulmonary hypertension. Am J Physiol Heart Circ Physiol 302:H2381-H2395.
7. Bogaard HJ, Abe K, Vonk Noordegraaf A, and Voelkel NF (2009) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:794-804.
8. Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, and Berger RM (2013) A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol 169:183-189.
9. Bruneau BG, Piazza LA, and de Bold AJ (1997) BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273:H2678-H2686.
10. Bruner LH, Hilliker KS, and Roth RA (1983) Pulmonary hypertension and ECG changes from monocrotaline pyrrole in the rat. Am J Physiol 245:H300-H306.
11. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, and Archer SL (2012) Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) 90:31-43.
12. Freund-Michel V, Guibert C, Dubois M, Courtois A, Marthan R, Savineau JP, and Muller B (2013) Reactive oxygen species as therapeutic targets in pulmonary hypertension. Ther Adv Respir Dis 7:175-200.
13. Guihaire J, Bogaard HJ, Flécher E, Noly PE, Mercier O, Haddad F, and Fadel E (2013) Experimental models of right heart failure: a window for translational research in pulmonary hypertension. Semin Respir Crit Care Med 34:689-699.
14. Hale SL, Shryock JC, Belardinelli L, Sweeney M, and Kloner RA (2008) Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 44: 954-967.
15. Hoeper MM, Galiè N, Simonneau G, and Rubin LJ (2002) New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1209-1216.
16. Hoorn CM and Roth RA (1992) Monocrotaline pyrrole alters DNA, RNA and protein synthesis in pulmonary artery endothelial cells. Am J Physiol 262: L740-L747.
17. Lappin PB and Roth RA (1997) Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats. Toxicol Pathol 25:372-380.
18. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, et al. (2013) RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 1:115-122.
19. Malenfant S, Margaillan G, Loehr JE, Bonnet S, and Provencher S (2013) The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. Expert Rev Respir Med 7:43-55.
20. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, and Sitbon O (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62 (Suppl)D73-D81.
21. Minotti G (2013) Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs. J Pharmacol Exp Ther 346: 343-349.
22. Olsson KM, Nickel NP, Tongers J, and Hoeper MM (2013) Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 167:2300-2305.
23. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmüller P, et al. (2013) Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 128:2016-2025, 1-10.
24. Rain S, Handoko ML, Vonk Noordegraaf A, Bogaard HJ, van der Velden J, and de Man FS (2014) Pressure-overload-induced right heart failure. Pflugers Arch 466: 1055-1063.
25. Rajdev A, Garan H, and Biviano A (2012) Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis 55:180-186.
26. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC, and Sabbah HN (2008) Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 295:H2149-H2155.
27. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, and Archer SL (2013) QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 167:669-676.
28. Rocchetti M, Sala L, Rizzetto R, Staszewsky LI, Alemanni M, Zambelli V, Russo I, Barile L, Cornaghi L, Altomare C, et al. (2014) Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Cardiovasc Res 104:37-48.
29. Rosenberg HC and Rabinovitch M (1988) Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 255:H1484-H1491.
30. Shah SJ, Cuttica MJ, Beussink L, Mkrdichian H, Samari R, Benefield B, Selvaraj S, DeMatte JE, and Lee DC (2012) A pilot study of the effects of ranolazine on right ventricular structure and function, exercise capacity, and symptoms in pulmonary arterial hypertension. Circulation 126:A18974.
31. Shryock JC, Song Y, Rajamani S, Antzelevitch C, and Belardinelli L (2013) The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res 99:600-611.
32. Simon MA (2013) Assessment and treatment of right ventricular failure. Nat Rev Cardiol 10:204-218.
33. Sztrymf B, Souza R, Bertoletti L, Jaïs X, Sitbon O, Price LC, Simonneau G, and Humbert M (2010) Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 35:1286-1293.
34. Tanaka Y, Takase B, Yao T, and Ishihara M (2013) Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension. Am J Respir Cell Mol Biol 49:426-436.
35. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, Danner BC, Sag CM, Hund TJ, Mohler PJ, Belardinelli L, et al. (2013) Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol 61:111-122.
36. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, and Vonk-Noordegraaf A (2011) Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58:2511-2519.
37. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, and Nicolls MR (2012) Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 40:1555-1565.
38. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, et al. (2013) Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 62 (Suppl)D22-D33.
39. Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, and Lakatta EG (1982) Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol 243:H941-H947.
40. Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker SP, Hintze TH, et al. (2011) Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 57:639-647.